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Introduction
Single-Use Bioreactors are now commonly used for Pro-
cess Development activities, as seeding bioreactors or to
produce Drug Substances. The advantages of this equip-
ment have been well demonstrated over the last years on
batch/fed-batch processes. Continuous processes were
widely applied in the past to increase the overall produc-
tivity of small bioreactors or for sensitive molecule pro-
duction. The process control, contamination risk and
complexity were the main concerns of this operation
mode. However, the bioprocessing trends and technology
evolution led to reconsidering the perfusion processes.
The aim of this study was to combine standard single-use
bioreactors with different perfusion technologies and to
compare productivity and molecule quality.
Methods
A CHO cell line producing a mAb was thawed and ampli-
fied in shake flasks using Cellvento™ CHO-100 medium.
When a sufficient amount of cells was reached, 2 Mobius®
CellReady 3L bioreactors were launched in parallel: one in
batch mode and one in perfusion mode using Cellvento™
CHO-100 medium. Two perfusion technologies were
assessed: the Fibra-Cel® Disks (Eppendorf) and the Alter-
native Tangential Flow (Refine) ones. The Mobius®
CellReady 3L bioreactor was not modified to perform per-
fusion processes aseptically transferred into a Mobius®
CellReady 3L bioreactor through the probe port. Regard-
ing the ATF™ technology, an ATF-2 system was first
washed with water then autoclaved and welded to the har-
vest line of a Mobius® CellReady 3L bioreactor. The bior-
eactor conditions were 37°C with pH maintained between
6.80- and 7.10. The Dissolved Oxygen set point was 50%
and stirrer speed 104 rpm. The viable cell density, viability,
metabolism and titers were measured at least daily. The
perfusion was initiated at 0.5 vvm when the lactate was
above 0.5 g/L and increased daily based on glucose and
lactate levels up to 1 vvm for the Fibra-Cel ® technology
and up to 2 vvm for the ATF™ one. In order to increase
the oxygen transfer at high cell density, a decision tree was
applied. For the Fibra-Cel® technology, the mAb was col-
lected in harvest bags welded to a side port while for the
ATF™, the molecule remained inside the Mobius® Cell-
Ready 3L bioreactor with the use of a 50 kDa hollow fiber.
In order to measure the quality of the mAb produced,
samples were collected on day 7, day 10 and the last bior-
eactor day. Titers and HCP levels were directly measured
on harvest while SE-HPLC and cIEF were performed on
ProSep® Ultra Plus eluates.
Results
As expected, the cells grew on Fibra-Cel® Disks after 2
days. Thus only a few cells were in suspension from day
3 to day 14 (end of the bioreactor). Regarding the
ATF™ technology, a maximum cell density of 33 mil-
lions cells/mL was reached (Figure 1).
The glucose concentration was well maintained
between 5 and 6,5 g/L while the lactate was not above
1.5 g/L in perfusion bioreactors. A steady state was
maintained over several days. The global productivity of
each process mode was calculated and compared to the
batch one. The perfusion technologies increased the
mAb quantity obtained compared to a batch mode. The
ATF™ technology increased the final mAb titer by 2.9
fold and the Fibra-Cel® technology increased the mAb
quantity by 1.2 fold (Table 1).
The quality attributes of the mAb obtained in batch and
perfusion modes were also compared. The molecule pro-
duced during the perfusion processes was more acid than
the ones produced in batch and fed-batch modes. There-
fore the mAb produced with Fibra-Cel® and ATF™ tech-
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higher half-life than the molecule produced in batch and
fed-batch modes. Regarding the Host Cell Proteins, Low
Molecular Weight and High Molecular Weight overall
contents, the ATF™ technology generates more contami-
nants while the Fibra-Cel® reduces them compared to a
batch process (Table 1). Finally, the upstream cost to
reach the ATF™ quantity was compared between batch
and perfusion processes at different scales. The ATF™
technology can reduce process cost in disposable bioreac-
tors whatever the scale compared to the batch mode while
the Fibra-Cel® process cost is higher due to higher med-
ium quantity necessary (Table 1).
Conclusions
Without any modification of the Mobius® CellReady 3L
bioreactor, we were able to demonstrate the compatibility
of this single use bioreactor to a mAb perfusion process.
Using two different technologies, the overall perfor-
mances, molecule quality, contaminant level and cost
were compared. This study demonstrates the flexibility of
existing disposable bioreactors to new bioprocessing
technologies.
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Figure 1 Viable cell density in suspension in batch and perfusion processes measured in Mobius® CellReady 3L.
Table 1 Global productivity, Host cell Proteins, High
Molecular Weight and Low Molecular Weight contents in
perfusion processes compared to batch ones reached in
Mobius® CellReady 3L bioreactor in addition to upstream
cost to reach ATF™ mAb quantity, in perfusion processes







Final Titer 100% 121% 290%
Host Cell Proteins 100% 28% 144%
High Molecular Weight 100% 87% 198%
Low Molecular Weight 100% 68% 107%
Upstream cost at 3L GLP Scale 100% 108% 47%
Upstream cost at 50L GLP Scale 100% 175% 84%
Upstream cost at 200L GMP Scale 100% 134% 47%
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